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Abstract
Background: Exposure to the chemotherapeutic alkylating agent thiotepa during brain development leads to neurological
complications arising from neurodegeneration and irreversible damage to the developing central nerve system (CNS).
Administration of single dose of thiotepa in 7-d postnatal (P7) rat triggers activation of apoptotic cascade and widespread
neuronal death. The present study was aimed to elucidate whether nicotinamide may prevent thiotepa-induced
neurodegeneration in the developing rat brain.
Methodology/Principal Findings: Neuronal cell death induced by thiotepa was associated with the induction of Bax,
release of cytochrome-c from mitochondria into the cytosol, activation of caspase-3 and cleavage of poly (ADP-ribose)
polymerase (PARP-1). Post-treatment of developing rats with nicotinamide suppressed thiotepa-induced upregulation of
Bax, reduced cytochrome-c release into the cytosol and reduced expression of activated caspase-3 and cleavage of PARP-1.
Cresyl violet staining showed numerous dead cells in the cortex hippocampus and thalamus; post-treatment with
nicotinamide reduced the number of dead cells in these brain regions. Terminal deoxynucleotidyl transferase (TdT)-
mediated dUTP nick end-labeling (TUNEL) and immunohistochemical analysis of caspase-3 show that thiotepa-induced cell
death is apoptotic and that it is inhibited by nicotinamide treatment.
Conclusion: Nicotinamide (Nic) treatment with thiotepa significantly improved neuronal survival and alleviated neuronal
cell death in the developing rat. These data demonstrate that nicotinamide shows promise as a therapeutic and
neuroprotective agent for the treatment of neurodegenerative disorders in newborns and infants.
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Introduction
Neurological dysfunction is a well-known adverse effect of
cancer therapeutics [1]. Chemotherapy, for example, is associated
with an increased occurrence of neurodegenerative disorders that
impair the development of higher mental abilities, cognitive status
and academic achievements in children [2,3,4]. Furthermore, the
toxic effects of anticancer agents can lead to neurological disorders
such as cerebral infarction, seizures, leukoencephalopathy and
others [5]. Chemotherapeutic toxicity has been shown to induce
neuronal cell demise through the activation of two well-known
apoptotic cascades [6,7,8]. Under the influence of some anticancer
drugs, cytochrome c is released into the cytosol; in the presence of
ATP, such release causes oligomerization of Apaf-1 (apoptotic
protease activating factor 1) and activation of caspase-9 and
caspase-3 [9,10,11,12]. One such drug is thiotepa (N,N9N9-
triethylenethiophosphoramide), an alkylating agent used for
treatment of breast, colon, lung, brain, gastric, bladder and
ovarian cancers; administration of thiotepa can also lead to poly
(ADP-ribose) polymerase (PARP-1) activation [13,14].
Nicotinamide, an amide of vitamin B3, is the precursor of
coenzyme b-nicotinamide adenine dinucleotide (NAD
+). NAD
+ is
considered to be necessary for cellular functions and metabolism
[15]. Nicotinamide is well known to exhibit preclinical efficacy and
to protect against neurological damage, but the exact mechanism of
neuroprotection remains enigmatic. It is known that severe cellular
insult leads to increased activity of PARP-1, which causes NAD
+
depletion and apoptosis [14]. In the presence of nicotinamide, an
essential precursor to NAD
+, cellular NAD
+ stores are more
effectively replenished and damaged DNA is more effectively
repaired [15,16]. Nicotinamide improves neuronal survival follow-
ing a variety of insults, including free radical exposure and oxidative
stress [17,18]. Its protective function is thought to be based on its
numerous and diverse pharmacological effects, which include
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peroxidation, anti-inflammatory activity, and prevention of apop-
tosis [18,21]. Nicotinamide also modulates mitochondrial mem-
brane potential and the formation of pores, prevents cytochrome c
release into the cytosol, and inhibits caspase-9 and caspase-3 like
activities through mechanisms that are independent of those
involving the mitogen-activated protein MAP kinase p38 and the
c-Jun N-terminal kinases JNK [17,18,19,20,21,22].
Chemotherapy for cancer treatment is often a necessity, and
people diagnosed with cancer frequently receive chemotherapy in
spite of its severe neurotoxic effects. Because thiotepa is routinely
used as a chemotherapeutic agent, improvement of the neurolog-
ical outcome of neonates and infants who experience neurotoxicity
following treatment with this drug depends on advancing
understanding of the precise molecular mechanisms triggering
thiotepa-induced neurodegeneration and the development of
neuroprotective therapeutics. The present study aimed to examine
the protective role of nicotinamide against thiotepa-induced
neurodegeneration in developing rats. The results show that
nicotinamide effectively inhibits thiotepa-induced apoptotic neu-
rodegeneration in developing rats. However, more comprehensive
research and clinical trials will be required to determine whether
nicotinamide can be used in conjunction with chemotherapy for
prophylaxis of neurodegeneration or for the treatment of
anticancer drug-induced neurodegeneration.
Results
Effect of nicotinamide on thiotepa-induced upregulation
of Bax mRNA expression in the developing rat brain
Overexpression ofBaxleadstomitochondrialdysfunction andcell
death [23]. RT-PCR analysis was performed to examine whether
the thiotepa-induced upregulation of Bax mRNA levels could be
reversed by nicotinamide. After administration of a single dose
(30 mg/kg) of chemotherapeutic alkylating agent (thiotepa) [1] to
developing rats after 4 h, a significant increase in Bax mRNA levels
was found in the cortex and thalamus; no such change was seen in
the hippocampus (data not shown). Treatment of the animals with
nicotinamide shortly after thiotepa administration significantly
decreased Bax mRNA expression level in the cortex and thalamus
(Fig.1A).Nomarkedchangewas observed in the Bcl-2 mRNAlevels
in thiotepa-exposed developing rat cortex, hippocampus and
thalamus either with or without nicotinamide treatment (Fig. 1B).
Effect of nicotinamide on thiotepa-induced upregulation
of Bax protein in the developing rat brain
To explore the molecular mechanisms of thiotepa-induced
apoptotic neurodegeneration and protection by nicotinamide, we
monitored the change in the expression of apoptotic proteins in
the mitochondrial pathway. The Bcl-2 family members, pro-
apoptotic Bax and anti-apoptotic Bcl-2, are the critical regulators
of the apoptotic pathway in mitochondria [24]. Therefore, we
measured the levels of Bax and Bcl-2 protein in the cortex,
hippocampus and thalamus of young rats after 4 h of thiotepa
treatment with and without nicotinamide. Bax levels in the cortex
and thalamus showed an upregulation on thiotepa treatment
compared to those of control animals. Treatment with nicotin-
amide significantly reversed thiotepa-induced upregulation of Bax
(Fig. 2A), while no marked difference was observed in the levels of
Bax in hippocampus after nicotinamide treatment alone (data not
shown). In agreement with the results of a previous investigation
[25], the expression level of Bcl-2 in the cortex, hippocampus and
thalamus of the drug-treated groups was unchanged as compared
Figure 1. Co-treatment effect of nicotinamide (Nic) on thiotepa-induced Bax and Bcl-2 mRNA levels. Representative RT-PCR analysis
shows expression levels of (A) Bax and (B) Bcl-2 mRNA in the cortex and thalamus of 7-day-old rat pups. Treatment with thiotepa (30 mg/kg for 4 h)
increased Bax mRNA levels in the cortex and thalamus. Treatment with (1 mg/g) of nicotinamide for 4 h significantly reduced thiotepa-induced up-
regulation of Bax mRNA levels in the cortex and thalamus, as shown. Detailed procedures are described in the Materials and Methods section. The
mRNA bands of RT-PCR were quantified using Sigma gel software; these differences are represented in the graph. GAPDH was used as mRNA loading
control. Density values are expressed as mean 6 SEM (n=5 animals/group). The density values on the Y-axis are expressed as arbitrary units (AU).
Statistical difference was determined using one-way analysis of variance (ANOVA) followed by Student’s t-test. (
aSignificantly different from CTL,
[cortex P,0.01 and thalamus P,0.01];
bSignificantly different from Nicotinamide, [cortex P,0.001 and thalamus P,0.05];
cSignificantly different from
Thiotepa + Nicotinamide, [cortex P,0.01 and thalamus P,0.05];
dSignificantly different from Thiotepa, [cortex P,0.01 and thalamus P,0.05]).
doi:10.1371/journal.pone.0027093.g001
Effect of Nicotinamide against Thiotepa
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thiotepa for 4 h results in an increase in Bax/Bcl-2 ratio, favoring
neuroapoptosis, while nicotinamide supplementation significantly
reduced Bax/Bcl-2 ratio, favoring neuroprotection.
Effect of nicotinamide on thiotepa-induced cytochrome c
release from mitochondria into cytosol
The mitochondrial apoptotic cascade requires the release of the
inter-mitochondrial membrane protein cytochrome c into the
cytosol; an increased cytosolic level of cytochrome c induces
activation of caspase-9 and caspase-3 and, subsequently, neuronal
death [12]. Protection by nicotinamide against thiotepa-induced
neurodegeneration might occur as a result of the inhibition of
cytochrome c release from mitochondria into the cytosol. Because
cytosolic cytochrome c is a marker for the activation of the
mitochondrial apoptotic cascade, we measured the levels of
cytosolic cytochrome c in the cortex, hippocampus and thalamus.
Four hours after administration of thiotepa, we found that in the
cortex and thalamus, increased levels of Bax correlated with
increases in cytosolic cytochrome c levels; no significant difference
in the cytosolic level of cytochrome c was observed in the
hippocampus (data not shown). Administration of nicotinamide
with thiotepa treatment resulted in significantly reduced cyto-
chrome c release from mitochondria into cytosol compared to that
in animals treated with thiotepa alone (Fig. 3).
Effect of nicotinamide on thiotepa-induced expression of
active caspase-3 in the developing rat brain
Caspases are cysteine proteases that play a key role in apoptosis
[26]. We therefore examined whether the prevention of
mitochondrial membrane depolarization and cytochrome c release
by nicotinamide occurs at the level of downstream cellular
pathways such as the inhibition of activated caspase-3. We
measured the levels of activated caspase-3 in the cortex,
hippocampus and thalamus by western blotting. Compared to
controls, levels of activated caspase-3 increased significantly in the
cortex and thalamus after thiotepa administration (Fig. 4A); no
marked difference was observed in the level of activated caspase-3
in the hippocampus (data not shown). Because we detected low
levels of activated caspase-3 in the control group also, tissue
extraction may induce low levels of caspase-3 activation; however,
the levels were significantly lower than those in the experimental
groups. Nicotinamide treatment with thiotepa significantly de-
creased the level of activated caspase-3 in both brain regions
compared to that in animals treated with thiotepa alone.
Effect of nicotinamide on thiotepa-induced cleavage of
PARP-1 in the developing rat brain
Despite its function in DNA repair, overactivation of PARP-1 in
neuronal excitotoxicity induces cell death [27]. In our experi-
ments, western blot analysis was used to determine whether the
elevated levels of activated caspase-3 observed in the cortex and
thalamus of developing rats treated with thiotepa led to the
cleavage of PARP-1 as occurs during apoptosis. The level of
cleaved PARP-1 in the cortex and thalamus of thiotepa-treated
animals was significantly enhanced compared to that in the control
and nicotinamide-treated groups. Nicotinamide treatment after
thiotepa resulted in a remarkable decrease in the level of full-
length (116 Kda) PARP-1 and a concomitant decrease in its
89 Kda caspase-3 cleaved products in the cortex and thalamus
Figure 2. Co-treatment effect of nicotinamide (Nic) on thiotepa-induced expression of Bax and Bcl-2 protein levels. Representative
Western blot analysis shows the expression levels of (A) Bax and (B) Bcl-2 protein in the cortex and thalamus of a 7-day-old rat. Treatment with
(30 mg/kg) of thiotepa for 4 h increased Bax protein levels in the cortex and thalamus. Treatment with (1 mg/g) of nicotinamide for 4 h inhibited
thiotepa-induced upregulation of Bax protein levels in the cortex and thalamus, as shown. The protein bands of the Western blot were quantified
using Sigma gel software; their differences are represented in the graph. Actin was used as a protein loading control. Density values, expressed as
mean 6 SEM (n=5–6 animals/group), of Bcl-2 and Bax proteins are presented. The density values on the Y-axis are expressed as arbitrary units (AU).
Statistical difference was determined using one-way analysis of variance (ANOVA) followed by Student’s t-test. (
aSignificantly different from CTL,
[cortex P,0.001 and thalamus P,0.05];
bSignificantly different from Nicotinamide, [cortex P,0.01 and thalamus P,0.001];
cSignificantly different
from Thiotepa + Nicotinamide, [cortex P,0.01 and thalamus P,0.05];
dSignificantly different from Thiotepa, [cortex P,0.01 and thalamus P,0.05]).
doi:10.1371/journal.pone.0027093.g002
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increase in PARP-1 cleavage occurs in the cortex and thalamus of
the developing rat brain after exposure to thiotepa and that
nicotinamide significantly reduces the levels of thiotepa-induced
cleaved PARP-1 in both of these brain regions, such that the levels
remain similar to those observed in control animals.
Effect of nicotinamide on caspase-3 expression in the
developing rat brain 24 h after thiotepa treatment
Increased expression of active caspase-3 protein contributes to
neuronal cell death. In order to investigate the role of activated
caspase-3 in the pathogenesis of neuronal death after thiotepa
treatment, RT-PCR and western blot findings were supplemented
by immunohistochemical analysis. Expression of active caspase-3
was analyzed in the cortex, hippocampus and thalamus after 24 h
of thiotepa treatment. In the cingulate cortex and LDN of
thalamus of thiotepa-treated rats, numerous injured and dead
neurons with strong active caspase-3 immunoreactivity were
observed (Fig. 4C, panels Dd and Ff); however, no active
caspase-3 immunoreactivity was observed in the CA1 region of
hippocampus (Fig. 4C, panel Ee). The number of active caspase-3-
positive cells in the cortex and thalamus progressively decreased
when nicotinamide was administered with thiotepa (Fig. 4C,
panels Gg and Ii).
Effect of nicotinamide on thiotepa-induced
neurodegeneration in the developing rat brain
Nissl staining was performed after 24 h to examine the extent of
neuronal cell death induced by thiotepa and to assess protection by
nicotinamide in the cortex, hippocampus and thalamus of the
developing rat brain. Nissl staining identifies all structures,
particularly the nucleus and nucleic acids, which appear violet,
while neurons appear faintly blue. This method allowed clear
identification of dead neuronal cells (i.e., those with large or small
condensed, fragmented and dark nuclei and apoptotic bodies) in
the cingulate cortex, CA1 of hippocampus and LDN of thalamus.
Significantly increased vacuolization, neuronal loss, and tissue
breakdown were seen in the anterior cingulate cortex, CA1 of
hippocampus and LDN of thalamus of thiotepa-treated animals
(Fig. 5, panels F, G and H) as compared to control animals; in
control animals these brain regions appeared morphologically
normal (Fig. 5, panels C, D and E). The number of degenerated
neurons was significantly higher in the cortex and thalamus than
in the hippocampal region, which showed a low level of cell death.
Treatment of nicotinamide with thiotepa was associated with
significantly less vacuolization and neuronal loss in these brain
regions (Fig. 5, panels I, J and K).
DNA damage is one of the hallmarks of apoptosis. Visualization
of DNA damage is possible using TUNEL staining, an assay for
Figure 3. Co-treatment effect of nicotinamide on thiotepa-induced cytosolic cytochrome c levels. Representative Western blot analysis
of cytochrome c levels in the cortex and thalamus of 7-day-old rats. Significant increases in the cytosolic level of cytochrome c in the cortex and
thalamus after administration of thiotepa are shown. Treatment with nicotinamide for 4 h significantly reduced thiotepa-induced cytosolic
cytochrome c levels in cortex and thalamus, as shown. The protein bands of the Western blot were quantified using Sigma gel software analysis; their
differences are represented in the graph. Actin reactivity was used as a protein loading control. Density values, expressed as mean 6 SEM (n=5–6
animals/group), for cytochrome c and activated caspase-9 are presented. The density values on the Y-axis are expressed as arbitrary units (AU).
Statistical difference was determined using one-way analysis of variance (ANOVA) followed by Student’s t-test. (
aSignificantly different from CTL,
[cortex P,0.05 and thalamus P,0.05]);
bSignificantly different from Nicotinamide, [cortex P,0.05 and thalamus P,0.05];
cSignificantly different from
Thiotepa + Nicotinamide, [cortex P,0.01 and thalamus P,0.01];
dSignificantly different from Thiotepa, [cortex P,0.01 and thalamus P,0.01]).
doi:10.1371/journal.pone.0027093.g003
Effect of Nicotinamide against Thiotepa
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The nuclear morphology of brain tissue was evaluated with
TUNEL and DAPI staining. Thiotepa-induced neuroapoptosis in
developing rat brain cortex and thalamus resulted in the presence
of apoptotic bodies and nuclear fragmentation revealed by
TUNEL and DAPI staining. Compared to control animals
Figure 4. Co-treatment effect of nicotinamide on thiotepa-induced expression of active caspase-3 and cleavage of PARP-1. (A)
Representative Western blot analysis of cleaved caspase-3 levels in the cortex and thalamus of rats. Thiotepa administration resulted in a significantly
enhanced level of expression of active caspase-3. Treatment with nicotinamide significantly reduced thiotepa-induced activated caspase-3 levelsi n
both cortex and thalamus as compared to control group. Detailed procedures are described in the Materials and Methods section. The protein bands
of Western blots were quantified using Sigma gel software, and their differences are represented in the graph. Actin reactivity was used as a protein
loading control. Density values, expressed as mean 6 SEM (n=5–6 animals/group), of the caspase-3 protein are presented. The density values on the
Y-axis are expressed as arbitrary units (AU). Statistical difference was determined using one-way analysis of variance (ANOVA) followed by Student’s t-
test. (
aSignificantly different from CTL, [cortex P,0.05 and thalamus P,0.05];
bSignificantly different from Nicotinamide, [cortex P,0.05 and thalamus
P,0.01];
cSignificantly different from Thiotepa + Nicotinamide, [cortex P,0.05 and thalamus P,0.05];
dSignificantly different from Thiotepa, [cortex
P,0.05 and thalamus P,0.05]). (B) Representative Western blot analysis of cleaved PARP-1 levels in the cortex and thalamus of rats. Thiotepa
administration resulted in significantly enhanced expression levels of active caspase-3, and caspase-3 mediated a high level of cleaved 89-kDa
apoptosis-related fragment of PARP-1. As shown, treatment with nicotinamide significantly reduced thiotepa-induced activated caspase-3 and
cleaved PARP-1 levels in both the cortex and thalamus when compared to control group. Density values, expressed as mean 6 SEM (n=5–6 animals/
group), for 89 Kda caspase-3 cleaved PARP-1 proteins are presented. Statistical difference was determined using one-way analysis of variance
(ANOVA) followed by Student’s t-test. (
aSignificantly different from CTL, [cortex P,0.001 and thalamus P,0.01];
bSignificantly different from
Nicotinamide, [cortex P,0.01 and thalamus P,0.05];
cSignificantly different from Thiotepa + Nicotinamide, [cortex P,0.01 and thalamus P,0.05];
dSignificantly different from Thiotepa, [cortex P,0.01 and thalamus P,0.05]). (C) Representative Photomicrographs showing immunohistochemical
analysis 24 h after treatment with 30 mg/kg thiotepa in the absence or presence of nicotinamide. Light micrographs show active caspase-3-positive
neurons in cingulate cortex and LDN of thalamus (Dd and Ff) after thiotepa treatment, but none in hippocampus (Ee). The arrows indicate dead
neuronal cells with high active caspase-3 expression. Treatment of nicotinamide (1 mg/g) with thiotepa resulted in a marked reduction in the number
of active caspase-positive neurons in the cortex and thalamus (Gg and Ii) compared to controls (Aa and Cc). Images are representative of staining
obtained in sections (3–5/group) prepared from at least 5–6 animals/group. (a–i=406) are magnified views from panels (A–I=206), Scale
bar=50 mm. Statistical difference was determined using one-way analysis of variance (ANOVA) followed by Student’s t-test. (
aSignificantly different
from CTL, [cortex P,0.001 and thalamus P,0.001];
bSignificantly different from Thiotepa + Nicotinamide, [cortex P,0.05 and thalamus P,0.01];
cSignificantly different from Thiotepa, [cortex P,0.01 and thalamus P,0.01]).
doi:10.1371/journal.pone.0027093.g004
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PLoS ONE | www.plosone.org 5 December 2011 | Volume 6 | Issue 12 | e27093Figure 5. Co-treatment effect of nicotinamide on thiotepa-induced neuronal cell death. Light micrographs of cresyl violet-stained
neurons in tissue sections of developing rat brain after thiotepa with nicotinamide. The majority of thiotepa-induced degenerating neuronal cells
(generally shrunken in appearance, as is commonly observed) are present in the anterior cingulate cortex, CA1 of hippocampus and LDN of thalamus
(F, G, and H). The arrows indicate shrunken and damaged neurons. Almost complete protection was observed (I, J and K), when nicotinamide was
administered with thiotepa. Images are representative of staining obtained in sections (3–5/group) prepared from at least 5–6 animals/group. (C–K)
of Nissl-stained brain tissue at higher magnification with 406objective field, Scale bar=20 mm. Statistical difference was determined using one-way
analysis of variance (ANOVA) followed by Student’s t-test. (
aSignificantly different from CTL, [cortex P,0.001, hippocampus P,0.05 and thalamus
P,0.001];
bSignificantly different from Thiotepa + Nicotinamide, [cortex P,0.01, hippocampus P,0.05 and thalamus P,0.01];
cSignificantly different
from Thiotepa, [cortex P,0.01, hippocampus P,0.05 and thalamus P,0.01]).
doi:10.1371/journal.pone.0027093.g005
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increased the number of TUNEL-positive shrunken cells with
small multi-DNA masses (typical features of apoptosis) in the
cortex and thalamus (Fig. 6, panels D and F) counterstained with
DAPI (Fig. 6, panels G and I). TUNEL-positive cells were not
detected in CA1 of hippocampus of thiotepa-treated rats (Fig. 6,
panels E and H). Most of the TUNEL-positive cells were in the
cortex and thalamus, and overlapping of TUNEL staining with
DAPI staining showed apoptotic neuronal death (Fig. 6, panels G
and I). Nicotinamide treatment with thiotepa significantly reduced
the number of TUNEL-positive cells in these brain regions (Fig. 6,
panels J and L).
Discussion
Neurotoxicity is a common and often dose-limiting complica-
tion of chemotherapy [28]. Despite intensive efforts at manage-
ment of the neurological side effects of chemotherapy in patients
and the development of neuroprotective agents, there is no
generally accepted therapy at the present time [29]. The use of
neuroprotective agents can reduce neurotoxicity resulting from
anticancer chemotherapy. Intensive research is therefore currently
being focused on the identification and understanding of
molecular and cellular mechanisms of neuroprotectants against
such toxicity [30]. A mitochondria- dependent apoptotic cascade
plays an important role in thiotepa-induced neurodegeneration
[31,32].Specifically, the normal functions of the central nervous
system depend on mitochondrial activity for regulating calcium
homeostasis, which itself serves as a regulator of several enzymatic
activities and cell processes including apoptosis [33].
Due to its high metabolic rate and relatively reduced capacity
for cellular regeneration, the brain is particularly susceptible to the
damaging effects of oxidative stress [34]. The chemotherapeutic
alkylating agent thiotepa has neurodegenerative effects in the
infant rat brain that appear to be associated with disruption of
mitochondrial energy metabolism, oxidative stress, and activation
of cell death cascades [1]. Our results show that the neuronal cell
death induced by single dose of alkylating agent thiotepa in the
developing rat brain is apoptotic, as revealed by the occurrence of
apoptotic bodies, nuclear fragmentation and activation of
caspases. Apoptotic signals amplify through mitochondria due to
changes in mitochondrial membrane permeability, which facilitate
the release of the apoptogenic factor cytochrome c, regulated by
the Bax and Bcl-2 proteins [35]. Activation of PARP-1 is a critical
event that directs toxic signaling towards apoptosis or necrosis. Its
cleavage facilitates DNA alteration and nuclear disassembly and
ensures completion of the energy-dependent cell death process
[36]. Activated caspase-3 cleaves PARP-1, which is an important
protein in DNA repair, thus promoting apoptosis; in contrast,
excessive activation of PARP-1 depletes NAD
+ and ATP, resulting
in necrosis [27,37]. Our results show that after 4 h of thiotepa
treatment, the level of expression of anti-apoptotic Bcl-2 was not
changed; this confirms the results of a previous study [25]. In
contrast, thiotepa induced upregulation of Bax and release of
cytochrome c into the cytosol. Activation of caspase-3 and
cleavage of PARP-1 by caspase-3 were analyzed in order to assess
the involvement of the mitochondrial apoptotic pathway [31] in
the neuronal degeneration caused by thiotepa. The expression of
Bax and Bcl-2 proteins exhibited trends similar to those of the
corresponding mRNA levels which is control by p53 [38].
Thiotepa-induced insult has been shown to increase mitochondrial
membrane permeability and lead to the release of cytochrome c,
the activation of caspase-9 and the subsequent activation of
caspase-3, all of which play key roles in apoptosis [12,26,39].
Nicotinamide is a necessary nutrient that acts as a protective
agent against neurodegeneration induced by a variety of insults
including oxidative stress [40,41,42]. In developing rats, its
systemic use provides significant protection against thiotepa-
induced apoptotic and necrotic cell death. The results presented
here show that treatment with nicotinamide inhibits thiotepa-
induced activation of the apoptotic cascade through downregula-
tion of proapoptotic Bax, thus counteracting thiotepa-induced
increases in Bax levels. As a result, mitochondrial membrane
potential is stabilized, release of cytochrome c is inhibited, and the
levels of active caspase-3 and the cleavage of PARP-1 are reduced,
which are involved in the activation of DNAses and the formation
of apoptotic bodies [43,44]. Our results clearly show that the
protective effect of nicotinamide against thiotepa involves the
maintenance of mitochondrial integrity and the concomitant
repression of Bax, inhibition of the mitochondrially-mediated
release of cytochrome c into the cytosol, inhibition of activated
caspase-3 and maintenance of NAD
+ levels, all of which contribute
to the inhibition of apoptotic and possible necrotic cell death in the
developing rat brain (Fig. 7).
Modulation of the PARP-1 cascade is a well-known strategy
used by cells to prevent ATP and NAD
+ depletion; such
modulation protects the developing brain against ischemia and
excitotoxic insults involving DNA damage. Pharmacological
inhibition or genetic disruption of PARP-1 can markedly reduce
cell death resulting from oxidative stress [45,46]. Under normal
physiological conditions, PARP-1 is thought to play a key role in
DNA repair, thereby contributing to the maintenance of cellular
genomic integrity [47]. However, high metabolic and oxidative
stress activates PARP-1 and depletes intracellular NAD
+ stores
[48,49]. Rapid depletion of NAD
+ and ATP is a suicide
response that can result in cell death by apoptosis or necrosis if
broken DNA strands are not repaired [27,50], as degree of
r e d u c t i o ni nt h el e v e lo fA T Pt h a tr e p r e s e n t st h et h r e s h o l d
between apoptotic and necrotic cell death [51,52,53]. Treat-
ment of developing rats with nicotinamide after thiotepa inhibits
induction of the apoptotic cascade due to inhibition of caspase-
3, which is responsible for cleavage of PARP-1; such treatment
thereby interferes with NAD
+ depletion and may inhibits
necrosis (Fig. 7) and other non-apoptotic cell death mechanisms
[20,54,55].
Immunohistochemical and TUNEL findings were consistent
with the molecular results; both showed that thiotepa treatment
significantly increased expression of active caspase-3 in the cortex
and thalamus while there was no significant change in the
hippocampus. Histomorphological analysis by Nissl staining
showed low levels of neuronal cell death in the hippocampal
region as well. The exact reason for this discrepancy is unknown;
one possible explanation is the involvement of neuronal apoptosis
inhibitory protein (NAIP), in the hippocampal region [56,57].
Whether or not NAIP is involved in the inhibition of alkylating
agent-induced degeneration of developing brain in hippocampus
remains to be determined. Histomorphological analysis also
showed that the cell death induced by thiotepa is more
pronounced and severe in the cortex and thalamus than in the
hippocampus, indicating that, in the developing rat, these brain
regions are more sensitive to thiotepa-induced apoptotic insult.
Here, we speculate that thiotepa-induced cell death in the cortex
and thalamus is mainly apoptotic and caspase-dependent, while in
the hippocampus, caspase-independent or non-apoptotic cell
death processes might be involved (Fig. 6). A relationship between
histomorphological neuronal death and cognitive deficits could not
be established; however, it is reasonable to suggest that protection
by nicotinamide against thiotepa might be beneficial for mental
Effect of Nicotinamide against Thiotepa
PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e27093Figure 6. Co-treatment effect of nicotinamide on thiotepa-induced apoptotic neurodegeneration. Representative photomicrographs of
TUNEL staining show apoptotic dead neuronal cells after thiotepa administration with nicotinamide. The arrows indicate thiotepa-induced TUNEL
stained apoptotic dead neurons (D and F) counterstained with DAPI (G and I) in the cortex and thalamus. Nicotinamide treatment effectively blocked
thiotepa-induced apoptosis, as evident from the lack of TUNEL-positive cells (J and L). Images are representative of staining obtained in sections (3–5/
group) prepared from at least 5–6 animals/group. (A–L) of TUNEL-stained brain tissue at higher magnification with 406 objective field, Scale
bar=20 mm. Statistical difference was determined using one-way analysis of variance (ANOVA) followed by Student’s t-test. (
aSignificantly different
from CTL, [cortex P,0.001 and thalamus P,0.001];
bSignificantly different from Thiotepa + Nicotinamide, [cortex P,0.01 and thalamus P,0.01];
cSignificantly different from Thiotepa, [cortex P,0.01 and thalamus P,0.01]).
doi:10.1371/journal.pone.0027093.g006
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other behavioral outcomes.
In the present study, we found that nicotinamide treatment of the
developing rat brain with thiotepa was associated with a decrease in
thiotepa-induced apoptotic and necrotic cell death and improved
brain histomorphological outcomes. Because nicotinamide can
easily reach the brain [58,59], it might be able to function as a
critical protective agent in various neurodegenerative paradigms in
which the mitochondrial apoptotic pathway is involved. Our data
suggests that stabilization of the mitochondrial apoptotic pathway
by nicotinamide may protect developing neurons treatment with
anticancer drugs or other forms of excitotoxic insult. These findings
open new avenues for examining the role of nicotinamide as a
promising and safe neuroprotective agent for the treatment of
neurodegenerativedisorders[59].Otherneuroprotectantsthathave
similar modes of action might also be developed to stabilize the
apoptotic cascade caused by various toxic agents in infants.
Conclusions
Our results support the hypothesis that nicotinamide treatment
protects against thiotepa-induced neurodegeneration in the
developing rat brain, interfering with apoptotic cell death.
Nicotinamide could be a potential remedy for neurodegenerative
conditions caused by toxic effects of various neurotoxic drugs in
newborns or infants. More work is clearly needed to comprehen-
sively assess the neuroprotective role of nicotinamide.
Materials and Methods
Animals
Seven-day-old Sprague-Dawley rat pups (average body weight
15 g) were used in all experimental paradigms and were equally
distributed into four different groups (control, thiotepa, nicotin-
amide, and thiotepa + nicotinamide). All efforts were made to
minimize the number of animals used and their suffering. All the
experimental procedures were approved (Approval ID: 125) by the
animal ethics committee (IACUC) of the Division of Applied Life
Sciences, Department of Biology, Gyeongsang National University
South Korea.
Drug treatment
Protective effect of nicotinamide against thiotepa was observed
at different time points i.e. (2 h) pre-treatment of thiotepa, Co-
treatment of thiotepa and (2 h) post-treatment of thiotepa. At all
Figure 7. A schematic diagram representing the hypothetical mechanism by which nicotinamide protects against thiotepa-induced
neurodegeneration in the brain of the developing rat. Thiotepa-induced neurodegeneration is caused by the overactivation of mitochondria-
dependent apoptosis, beginning with the down-regulation of Bax, an increase in cytochrome c release from mitochondria to cytosol, expression of
activated capase-3, cleavage of PARP-1 and necrosis by overactivation and cleavage of PARP-1 and depletion of NAD
+ (blue arrow). PARP-1 activation
and formation of Poly ADP-ribose PAR in the nucleus, which translocates to the cytosol to induce caspase-independent cell death (black arrow).
Nicotinamide, as indicated by the X sign, inhibits several key elements in the apoptotic cascade beginning with the down-regulation of Bax, a
decrease in cytochrome c release from mitochondria to cytosol, inhibition of activated caspase-3 and cleavage of PARP-1 and necrosis by the
inhibition of PARP-1 activation and prevention of ATP and NAD
+ depletion (red arrow), resulting in protection against thiotepa-induced apoptotic
and possible necrotic cell death.
doi:10.1371/journal.pone.0027093.g007
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effect was observed when used with thiotepa treatment. In our
experiments developing rats were injected subcutaneously with
(30 mg/kg) thiotepa with (1 mg/g) nicotinamide in 0.9% saline
solution. Animals were sacrificed 4–24 h after drug treatment.
Saline injections of equal volume were used as controls.
Reverse transcriptase-polymerase chain reaction (RT-PCR)
analysis
The cerebral cortex, hippocampus and thalamic cortex were
rapidly collected, separated and snap-frozen in liquid nitrogen.
Samples were kept at 280uC until further processing. Total
cellular RNA was isolated by acidic phenol/chloroform extraction.
The RNA was aliquoted and stored at 280uC until further use.
Then, 2 mg of total RNA was reverse-transcribed to single-
stranded cDNA using Oligo(dT)12–18 primer (Invitrogen, Carls-
bad, CA, USA) with M-MLV reverse transcriptase (Promega,
Madison, WI, USA). For PCR reactions, 4 ml of cDNA was
incubated with 20 pmol each of the forward and reverse primers
(Bioneer Corporation, Seoul, South Korea), and GoTaqHGreen
Master Mix 26 containing PCR buffer, 25 mM magnesium
chloride, 10 mM dNTP mix and Taq enzyme (Promega,
Madison, WI, USA) and amplified. The primers of each transcript
were as follows: Bcl-2, 5
/-CGACGACTTCTCCCGCCGC-
TACCGC-3
/(forward) and 5
/-CCGCATGCTGGGGCCGTA-
CAGTTCC-3
/(reverse), Bax, 5
/-GTGCACCAAGGTGCCG-
GAC-3
/ (forward) and 5
/-TCAGCCCATCTTCTTCCAGA-3
/
(reverse), and b-actin (as loading control), 5
/-GTGGGGC-
GCCCCAGGCACCA-3
/(forward) and 5
/CTCCTTAATGT-
CACGCACGATTTC-3
/ (reverse). The conditions for PCR
were: initial denaturation at 94uC for 5 min; 25 cycles of
denaturation at 94uC for 1 min, annealing for 1 min (Bcl-2,
68uC; Bax, 53uC; Caspase-3, 55uC; b-actin, 63uC), elongation at
72uC for 1 min and a final extension step at 72uC for 10 min on a
PC-812 Thermal Cycler (Astec, Fukuoka, Japan). The PCR
products were electrophoresed in 1% agarose gels containing
ethidium bromide for 25 min and exposed to UV light for
photography of the bands. The molecular sizes of the amplified
products were determined by comparison with molecular weight
markers (100 bp DNA ladder, Promega, Madison, WI, USA) run
in parallel with the PCR products. The densities of the mRNA
bands were analyzed using Molecular Analyst
TM, version 1.4.1
(Bio-Rad, Hercules, CA, USA).
Western blot analysis
In order to assess whether changes in the mRNA expression
profiles of Bax and Bcl-2 were matched by corresponding changes
in protein levels in the developing rat pups, the amounts of these
proteins were determined in the control, thiotepa, nicotinamide
and thiotepa-plus- nicotinamide treated animals. Seven-day-old
rats were killed after treatment with (1 mg/g) nicotinamide
immediately after administration of (30 mg/kg) of thiotepa for
4 h; the brains were rapidly removed, the cortex, hippocampus
and thalamus were carefully dissected and the tissue was frozen in
dry ice. The brain tissues were homogenized in 0.2 M PBS with
protease inhibitor cocktail. The protein concentration was
measured using Bio-Rad protein assay solution. Equivalent
amounts of protein (40 mg per sample) were electrophoresed on
10–15% SDS-PAGE gels under reducing conditions and trans-
ferred to a polyvinylidene difluoride (PVDF) membrane (Santa
Cruz Biotechnology, Santa Cruz, CA, USA). Prestained protein
markers, broad range (6–175 kDa, New England Biolabs Inc.,
Ipswich, MA, USA) were run in parallel for detection of the
molecular weights of the proteins. The membrane was blocked
with 5% (w/v) skimmed milk in order to reduce non-specific
binding and immunoblotting was performed using rabbit-derived
anti-Bcl-2, anti-Bax, and anti-caspase-3, anti-PARP-1 antibodies
and goat-derived polyclonal anti-cytochrome c (1:500; Santa Cruz
Biotechnology, Santa Cruz, CA, USA). Anti-b-actin antibody
(1:500; Sigma, St. Louis, MO, USA) was used as a control to
confirm uniform loading. Membranes were probed with a goat-
derived horseradish peroxidase-conjugated anti-rabbit IgG
(1:1000; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and
immunocomplexes were visualized using enhanced chemilumines-
cence ECL-detecting reagent (Amersham Pharmacia Biotech,
Western blotting detection reagents). The X-ray films were
scanned and the optical densities of the Western blots were
analyzed by densitometry using the computer-based Sigma Gel,
version 1.0 (SPSS, Chicago, IL, USA).
Tissue collection and sample preparation
Animals were sacrificed 24 h after drug treatment. Brain
sections from control rats and rats subjected to thiotepa followed
by nicotinamide for 24 h were analyzed. For tissue analysis (n=5–
6 per group), developing rat pups were perfused transcardially
with 4% ice-cold paraformaldehyde followed by 16PBS; brains
were post-fixed in 4% paraformaldehyde overnight and then
transferred to 20% sucrose until they sank to the bottom of the
tubes. Brains were frozen in O.C.T compound (A.O. USA) and
16 mm sections were made in the coronal planes using a Leica
cryostat (CM 3050C, Germany). Sections were thaw-mounted on
probe-on plus charged slides (Fisher).
Immunohistochemical staining
Immunohistochemistry was performed as previously described
by [60], with some modifications. The slides were washed in
0.01 M PBS, quenched for 10 min in a solution of methanol
containing 3% hydrogen peroxide, and then incubated for 1 h in
blocking solution (2% BSA/0.2% milk/0.1% Triton X-100 in
PBS), followed by incubation overnight in rabbit anti-active
caspase-3 antiserum (Cell Signaling Technology, Beverly, MA)
diluted 1:1000 in blocking solution. Following incubation with
primary antiserum, the sections were incubated for 90 min in
secondary antiserum (goat anti-rabbit, 1:200 in blocking solution),
and then reacted in the dark with ABC reagents (standard
Vectastain ABC Elite Kit; Vector Laboratories, Burlingame, CA)
for 90 min. The sections were then washed twice with PBS and
incubated with VIP reagent (Vector VIP substrate kit for
peroxidase, Vector Labs, Burlingame, CA) to develop a purple
color. Images were viewed with a fluorescence light microscope.
Active caspase-3-positive cells in the different regions of each
section were counted by observers blinded to the treatment
conditions.
Cresyl violet staining
Cresyl violet was used to stain tissue sections for histological
examination and measurement of neuronal loss. Nissl histology of
developing rat brain and the presence and absence of dead and
injured neurons were analyzed on microscope slides mounted
16 mm thick brain sections. Sections derived from all investigated
rat pups were defatted in ascending alcohols (70–100%), hydrated
in descending alcohols (95–70%), washed in acetate buffer pH 5.0
and subsequently stained with a 0.25% cresyl violet for
approximately 15 min. Section were then washed with distilled
water and dehydrated in graded ethanol. Images were viewed with
a fluorescence light microscope. Neurons in the different regions of
each section (5–6/group) were counted manually by observers
blinded to the treatment conditions.
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To detect typical features of apoptosis, nuclear DNA was
stained with TUNEL (GenScript Corporation, USA) and
counterstained using 49,6-diamidino-2-phenylindole (DAPI). In
situ detection of apoptotic cell death was performed using terminal
deoxynucleotidyl transferase (TdT)-mediated dUTP nick end-
labeling (TUNEL) on cryosections (16 mm) of aggregates. TUNEL
staining was performed according to supplier recommendations
using the In Situ Cell Death Detection kit Fluorescein (Genescript,
NJ, USA). Aggregate cryosections (16 mm) were incubated with
DAPI (Molecular Probes, Eugene, OR, USA) for 10 min at room
temperature and then rinsed with distilled water. Glass cover slips
were mounted on glass slides with mounting medium. A DAPI
filter was used to detect the DAPI staining (blue color) and an
FITC filter was used was to detect TUNEL staining (green color).
TUNEL-positive (green) and DAPI-positive (blue) staining pat-
terns were acquired by use of a confocal laser scanning microscope
(Fluoview FV 1000, Olympus, Japan). TUNEL-positive cells in the
different regions of each section were counted by observers blinded
to the treatment conditions.
Data analysis and statistics
Bands from RT-PCR and Western blots were scanned and
analyzed by densitometry using the Sigma Gel System (SPSS Inc.,
Chicago, IL). Density values were expressed as mean 6 SEM.
Statistical difference was determined using one-way analysis of
variance (ANOVA) followed by Student’s t-test. P values less than
0.05 were considered significant.
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